🏛️ Verified NIH Record • Updated 2026-06-13
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas (NCT05463263)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Step Pharma, SAS
🩺 Plain-English Summary (8th-Grade Level)
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Who can join: Review the eligibility criteria below.
Location: Colorado Blood Cancer Institute — Denver, Colorado
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Colorado Blood Cancer Institute — Denver, Colorado
- Florida Cancer Specialists — Sarasota, Florida
- Memorial Sloan Kettering — New York, New York
- Hôpital Saint-Louis — Paris, Paris
- The Centre Léon Bérard — Lyon,
- Institut Paoli Calmettes — Marseille,
- CHU de Nantes — Nantes,
- Institut Gustave Roussy — Villejuif,
- University Hospitals of Leicester NHS Trust — Leicester,
- Imperial College / Clinical Trials Unit, Hammersmith Hospital — London,
- The Christie — Manchester,
- Nottingham City Hospital — Nottingham,
- Churchill Hospital — Oxford,
- Derriford Hospital — Plymouth,
- The Royal Marsden — Sutton,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.